U.S. drugmaker Eli Lilly raised third-quarter revenue by 39%, fueled by global demand for its obesity and diabetes treatments, and lifted its full-year guidance again just two months after its previous increase. The day after the earnings release, on October 29 local time, the stock jumped 6.6% to $1,373.7, setting a new all-time high, while its market capitalization swelled to $1.224 trillion, overtaking both Samsung Electronics and Berkshire Hathaway. It ranks 12th globally by market value.

Lilly’s third-quarter results showed revenue of $24.4 billion and net income of $6.45 billion. Revenue rose 39% and net income 16% from a year earlier. Cumulative revenue for the first nine months reached $67.17 billion, up 46% year over year, while net income rose 50% to $20.942 billion.

The growth engine was unmistakably the GLP-1 class of obesity and diabetes treatments. The diabetes drug Mounjaro brought in $10.7 billion in the third quarter, up 65% from a year earlier, while Zepbound, the obesity treatment with the same active ingredient, grew 49% to $5.3 billion. Tirzepatide, the ingredient in both products, generated combined sales of $43.768 billion in the first nine months, accounting for 65% of Lilly’s total revenue. Mounjaro’s cumulative sales rose 89% to $29.328 billion, while Zepbound’s climbed 56% to $14.44 billion.

ItemQ3 ResultsYear-over-YearNine-Month CumulativeTotal Revenue$24.4 billion+39%$67.17 billionNet Income$6.45 billion+16%$20.942 billionMounjaro$10.7 billion+65%$29.328 billionZepbound$5.3 billion+49%$14.44 billion

Growth was broad-based across regions. Third-quarter U.S. revenue rose 34% to $15.136 billion, while Europe grew 28% to $4.459 billion. China posted the highest growth rate among major markets, up 69% to $947 million. On a nine-month cumulative basis, U.S. revenue was $41.668 billion, Europe $12.219 billion and China $2.582 billion. China’s cumulative revenue growth rate reached 75%.

Citing that momentum, Lilly raised its full-year revenue guidance for this year to $91 billion–$92 billion. That lifts the top end by $5 billion from the prior guidance of $85 billion–$87 billion, just two months later. CEO David Ricks said Lilly “delivered another strong quarter and was able to raise our full-year outlook,” attributing the revenue growth to broad global demand for Mounjaro and Zepbound and expanded U.S. coverage of obesity treatment. The company said about $900 million in profit was reflected in revenue, including a $410 million milestone tied to Jardiance, the diabetes treatment it co-markets with Germany’s Boehringer Ingelheim.

The growth drivers extend beyond tirzepatide. Orforglipron, an oral small-molecule GLP-1 treatment approved in the U.S. in April, generated $281 million in cumulative sales from its second-quarter launch through the third quarter, of which $184 million was booked in the third quarter. Lilly also said retatrutide, a once-weekly triple hormone receptor agonist, produced more than double the weight-loss effect of Novo Nordisk’s Ozempic in a direct-comparison Phase 3 trial. The study, in patients with type 2 diabetes, met the primary endpoint and all key secondary endpoints at 80 weeks.

The results show the balance of power in the obesity treatment market still tilts toward Lilly. Novo Nordisk opened the market first with Wegovy and Ozempic, but Lilly has kept expanding prescriptions with its follow-on products, achieving 39% quarterly revenue growth. A trend toward broader insurance coverage of obesity treatment in the U.S. is also underpinning demand. Still, raising full-year guidance again after just two months also signals that market expectations are already high. Whether the oral newcomer and retatrutide win approval will be the next variable in coming quarters.

Lilly’s market value surpassing Samsung Electronics and Berkshire Hathaway reads as a signal that pharma and biotech now carry greater weight among the world’s largest companies by market capitalization. With Lilly projecting more than $90 billion in annual revenue from obesity treatment alone, whether global capital keeps flowing into healthcare growth stocks is the key question for the fourth quarter.